Iliac vein thrombosis
Conditions
Interventions
Experimental group:Thrombectomy catheter
Sponsors
The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, no gender limit; 2. Patients with acute or subacute iliofemoral vein thrombosis confirmed by definite imaging diagnostic evidence (color Doppler ultrasound or CT venography or venography); (Acute stage: duration of onset <=14 days; Subacute stage: 15 ~ 30 days of onset); 3. Patients or their legal guardians can understand the purpose of the study, are willing to cooperate with interventional surgery and follow-up, voluntarily participate in the study and sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Angiographic exclusion criteria: the guide wire is difficult or unable to pass through the lesion; 2. Patients with symptomatic pulmonary embolism; 3. Patients with postthrombotic syndrome; 4. Target vessel with stent implantation; 5. Patients who need to use test instruments to remove bilateral iliofemoral vein thrombosis in the same operation; 6. Known combination of target lesion thrombus, bacterial endocarditis, aortic dissection, and target lesion vascular malformation; 7. Recent (within 30 days) active bleeding, including severe intracranial, digestive and urinary tract bleeding; 8. History of hemorrhagic or ischemic stroke within 3 months; 9. Chronic liver disease (e.g., liver fibrosis) or significant biochemical evidence of abnormal liver function (alanine aminotransferase/aspartate aminotransferase > 3 times the upper limit of normal); 10. Serum creatinine > 2.0 mg/dl (177 umol/L); 11. Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg); 12. Those who have contraindicated the use of contrast agents, anticoagulants or suppositories; 13. Those with a life expectancy of less than 12 months; 14. Those who are pregnant or plan to become pregnant during the duration of the study; 15. Those who are participating in clinical trials of any other drug or medical device and have not yet been enrolled; 16. Other conditions that the investigator judged unsuitable for participation in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombosis clearance; | — |
Countries
China
Contacts
Public ContactLu Xinwu
The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed